Insulet Corp. closed $9.41 below its 52-week high ($279.77), which the company achieved on December 12th.
Bernstein raised the firm’s price target on Insulet (PODD) to $315 from $305 and keeps an Outperform rating on the shares as part of a broader ...
Shares of Insulet Corp. PODD shed 1.03% to $265.65 Tuesday, on what proved to be an all-around grim trading session for the ...
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Investor's Business Daily on MSN1d
Insulin Device Maker Has Analysts Turning Bullish
Insulet stock is near a buy point after gapping up on earnings. The company increased its full year sales guidance.
Buying $100 In PODD: If an investor had bought $100 of PODD stock 10 years ago, it would be worth $598.02 today based on a ...
TD Cowen raised the firm’s price target on Insulet (PODD) to $324 from $264 and keeps a Buy rating on the shares. The firm thinks Insulet will ...
Insulet (NASDAQ:PODD – Get Free Report) had its target price increased by investment analysts at TD Cowen from $264.00 to ...
Bank of America Securities analyst Travis Steed maintained a Buy rating on Insulet (PODD – Research Report) yesterday and set a price target of ...
Insulet Corporation ( NASDAQ:PODD ) saw a double-digit share price rise of over 10% in the past couple of months on ...
Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An ...
In December, a Massachusetts corporation won the largest jury verdict ever awarded under the federal Defend Trade Secrets Act (DTSA). The award ...